Arcturus therapeutics receives u.s. fda fast track designation for arct-810, mrna therapeutic candidate for ornithine transcarbamylase deficiency

San diego--(business wire)---- $arct #clinicaltrial--arcturus therapeutics holdings inc. (the “company”, “arcturus”, nasdaq: arct), a global late-stage clinical messenger rna medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the u.s. food and drug administration (fda) has granted fast track designation to arct-810, the company's mrna therapeutic candidate for ornithine transcarbamylase (otc) deficiency. fast tra.
ARCT Ratings Summary
ARCT Quant Ranking